394 - A retrospective study of cisplatin/vinorelbine versus capecitabine/vinorelbine as second-line or third-line treatment in advanced breast cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Metastatic
Presenter Yunpeng Liu
Authors Y. Liu1, S. Shi1, X. Qu1, J. Shi2, L. Zhang2, L. Xu2, Y. Teng3
  • 1Medical Oncology, The First Hospital of China Medical University, 110001 - Shenyang/CN
  • 2Department Of Oncology, The First Affiliated Hospital of China Medical University, 110001 - Shenyang/CN
  • 3Oncology Dept., The First Affiliated Hospital of China Medical University, 110001 - Shenyang/CN

Abstract

Purpose

To compare the efficacy and safety of cisplatin or capecitabine, both with vinorelbine, as second-line or third-line treatment in advanced breast cancer previously treated with anthracyclines and/or taxanes.

Methods

From June 2004 to November 2011, 62 advanced breast cancer patients were eligible. Patients (38) enrolled in group NP received VIN 25mg/m2 on day 1 and 8 combined with Cisplatin 75mg/m2 on day 1 of a 21-day cycle. Patients (24) enrolled in group NX received VIN 25mg/m2 on day 1 and 8 of a 21-day cycle combined with CAP 1000mg/m2 twice daily for 14 consecutive days followed by 7 days of rest. Tumor assessment was performed every 2 cycles according to RESIST criteria. Toxicity was assessed according to National Cancer Institute Common Toxicity Criteria (version 3.0).

Results

The overall response rate (ORR) in group NP was 47.4%, all were partial responses (PRs). In group NX, ORR was 33.3% (P = 0.275), with 4.2% CRs and 29.2% PRs. Median time to progression (TTP) was 6.1 months (range, 3.2-9.0 months) in group NP and 6.3 months (range, 4.1-8.5 months) in group NX(P = 0.783). COX regression showed no statistically significant difference (P = 0.782, OR = 0.920). Median overall survival (OS) was 28.8 months (range, 21.6-36.0 months) in group NP and 15.1 months (9.6-20.6 months) in group NX(P = 0.027, OR = 0.495). COX regression showed a statistically significant difference(P = 0.045). Neutropenia was the most frequent hematologic toxicity, with 57.9% grade 3/4 neutropenia observed in group NP and 38.1% in group NX(P = 0.145). 13.2% grade 3/4 vomiting was seen in group NP and no grade 3/4 vomiting in group NX. No grade 3/4 nephrotoxicity or hand-foot syndrome was noted in both groups.

Conclusion

Better OS was seen in group NP than in group NX. Treatment-related toxicity in both groups was manageable.

Disclosure

All authors have declared no conflicts of interest.